All In Biotech

Drug Trial Radar · NCT05570006

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABBV-668 in Subjects With Moderate to Severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Mar 16, 2023

Primary completion

Dec 23, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approximately 30 sites globally. Participants will receive oral capsules of ABBV-668 twice daily for 16 weeks and will undergo a 30 day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Conditions

  • Ulcerative Colitis

Interventions

  • ABBV-668Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Endoscopic ImprovementTime frame: Week 8
  2. Number of Participants With Adverse Events (AEs)Time frame: From the time of first study drug administration until 30 days after the last dose of study drug (Up to approximately 20 weeks)

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Gastro SB /ID# 249271

    Chula Vista, California

  • Ctr for Advanced Gastroenterol /ID# 249226

    Maitland, Florida

  • Atlantic Medical Research /ID# 249213

    Margate, Florida

  • Endoscopic Research, Inc. /ID# 249202

    Orlando, Florida

  • Gastroenterology Associates of Central Georgia, LLC /ID# 249278

    Macon, Georgia

  • NYU Langone Long Island Clinical Research Associates /ID# 250075

    Lake Success, New York

  • Columbia University Medical Center /ID# 250189

    New York, New York

  • Lenox Hill Hospital /ID# 250008

    New York, New York

  • Atrium Health /ID# 249273

    Charlotte, North Carolina

  • Options Health Research, LLC /ID# 249216

    Tulsa, Oklahoma

  • University of Pennsylvania /ID# 250012

    Philadelphia, Pennsylvania

  • Allegheny Singer Research Institute d/b/a AHN Research Institute /ID# 250079

    Pittsburgh, Pennsylvania

  • University of Pittsburgh MC /ID# 250071

    Pittsburgh, Pennsylvania

  • Gastroenterology Associates, P.A. of Greenville /ID# 249217

    Greenville, South Carolina

  • Quality Medical Research /ID# 251125

    Nashville, Tennessee

  • Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 249208

    Garland, Texas

  • Baylor College of Medicine /ID# 249203

    Houston, Texas

  • Southern Star Research Institute, LLC /ID# 249212

    San Antonio, Texas

  • Groupe Sante CHC - Clinique du MontLegia /ID# 248928

    Liège, Belgium

  • UZ Gent /ID# 248605

    Ghent, Oost-Vlaanderen, Belgium

  • Vitaz /Id# 248607

    Sint-Niklaas, Oost-Vlaanderen, Belgium

  • Universitair Ziekenhuis Leuven /ID# 248598

    Leuven, Vlaams-Brabant, Belgium

  • CHU Montpellier - Hopital Saint Eloi /ID# 251876

    Montpellier, Herault, France

  • Centre Medico Chirurgical Ambroise Pare Hartmann /ID# 252357

    Neuilly-sur-Seine, Île-de-France Region, France

  • CHU Grenoble - Hopital Michallon /ID# 252108

    La Tronche, Isere, France

  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 251875

    St-Priest-en-Jarez, Pays de la Loire Region, France

  • Gastromed Sp. z o.o /ID# 255664

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Medical Network Sp.z.o.o. WIP Warsaw IBD Point Profesor Kierkus /ID# 255663

    Warsaw, Masovian Voivodeship, Poland

  • Endoskopia Sp. z o.o. /ID# 255667

    Sopot, Pomeranian Voivodeship, Poland

  • H-T Centrum Medyczne Endoterapia /ID# 255666

    Tychy, Silesian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.